5 results
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC (2.5/5 µg, 5/5 µg), administered once daily by the RESPIMAT Inhaler, after 6 weeks of treatment.
The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 / 5 µg ; 5 / 5 µg) with tiotropium (5 µg), olodaterol (5 µg) and placebo on lung-hyperinflation and endurance time…
The objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium plus olodaterol fixed dose combination compared with the individual components tiotropium and olodaterol (delivered by…
The purpose of the study is to determine the safety and assess the efficacy of the combination of radium-223 dichloride and pembrolizumab in participants with stage IV NSCLC with bone metastases who are either treatment naïve or have progressed on…
Primary:Sub-study I:- To develop high-quality fast quantitative MRI protocol for multi-contrast imaging of tumour pathophysiology at 3T in esophageal cancer patientsSub-study II:- To determine inter- and intra-session test-retest characteristics of…